CC Quote, Financials, Valuation and Earnings

Innospec, Inc. has a net margin of -3.62% compared to The Chemours Co.'s net margin of 10.4%. The Chemours Co.'s return on equity of -93.92% beat Innospec, Inc.'s return on equity of 9.08%.

The Chemours Co. has a consensus price target of $16.67, signalling downside risk potential of -2.19%. On the other hand Innospec, Inc. has an analysts' consensus of $99.33 which suggests that it could grow by 22.3%. Given that Innospec, Inc. has higher upside potential than The Chemours Co., analysts believe Innospec, Inc. is more attractive than The Chemours Co..

The Chemours Co. has a beta of 1.629, which suggesting that the stock is 62.923% more volatile than S&P 500. In comparison Innospec, Inc. has a beta of 0.908, suggesting its less volatile than the S&P 500 by 9.191%.

The Chemours Co. has a quarterly dividend of $0.09 per share corresponding to a yield of 3.01%. Innospec, Inc. offers a yield of 2.11% to investors and pays a quarterly dividend of $0.87 per share. The Chemours Co. pays 174.61% of its earnings as a dividend. Innospec, Inc. pays out 36.65% of its earnings as a dividend. Innospec, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but The Chemours Co.'s is not.

The Chemours Co. quarterly revenues are $1.3B, which are larger than Innospec, Inc. quarterly revenues of $455.6M. The Chemours Co.'s net income of -$47M is lower than Innospec, Inc.'s net income of $47.4M. Notably, The Chemours Co.'s price-to-earnings ratio is 66.47x while Innospec, Inc.'s PE ratio is 17.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Chemours Co. is 0.44x versus 1.14x for Innospec, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

The Mosaic Co. has a net margin of -3.62% compared to The Chemours Co.'s net margin of 12.29%. The Chemours Co.'s return on equity of -93.92% beat The Mosaic Co.'s return on equity of 10.32%.

The Chemours Co. has a consensus price target of $16.67, signalling downside risk potential of -2.19%. On the other hand The Mosaic Co. has an analysts' consensus of $32.27 which suggests that it could grow by 9.66%. Given that The Mosaic Co. has higher upside potential than The Chemours Co., analysts believe The Mosaic Co. is more attractive than The Chemours Co..

The Chemours Co. has a beta of 1.629, which suggesting that the stock is 62.923% more volatile than S&P 500. In comparison The Mosaic Co. has a beta of 0.972, suggesting its less volatile than the S&P 500 by 2.822%.

The Chemours Co. has a quarterly dividend of $0.09 per share corresponding to a yield of 3.01%. The Mosaic Co. offers a yield of 0.75% to investors and pays a quarterly dividend of $0.22 per share. The Chemours Co. pays 174.61% of its earnings as a dividend. The Mosaic Co. pays out 154.02% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

The Chemours Co. quarterly revenues are $1.3B, which are smaller than The Mosaic Co. quarterly revenues of $3.5B. The Chemours Co.'s net income of -$47M is lower than The Mosaic Co.'s net income of $424.1M. Notably, The Chemours Co.'s price-to-earnings ratio is 66.47x while The Mosaic Co.'s PE ratio is 7.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Chemours Co. is 0.44x versus 0.79x for The Mosaic Co.. Usually stocks with elevated PS ratios are considered overvalued.

Metallus, Inc. has a net margin of -3.62% compared to The Chemours Co.'s net margin of -5.35%. The Chemours Co.'s return on equity of -93.92% beat Metallus, Inc.'s return on equity of -0.17%.

The Chemours Co. has a consensus price target of $16.67, signalling downside risk potential of -2.19%. On the other hand Metallus, Inc. has an analysts' consensus of $22.00 which suggests that it could grow by 25.14%. Given that Metallus, Inc. has higher upside potential than The Chemours Co., analysts believe Metallus, Inc. is more attractive than The Chemours Co..

The Chemours Co. has a beta of 1.629, which suggesting that the stock is 62.923% more volatile than S&P 500. In comparison Metallus, Inc. has a beta of 1.485, suggesting its more volatile than the S&P 500 by 48.499%.

The Chemours Co. has a quarterly dividend of $0.09 per share corresponding to a yield of 3.01%. Metallus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Chemours Co. pays 174.61% of its earnings as a dividend. Metallus, Inc. pays out -- of its earnings as a dividend.

The Chemours Co. quarterly revenues are $1.3B, which are larger than Metallus, Inc. quarterly revenues of $267.3M. The Chemours Co.'s net income of -$47M is lower than Metallus, Inc.'s net income of -$14.3M. Notably, The Chemours Co.'s price-to-earnings ratio is 66.47x while Metallus, Inc.'s PE ratio is 30.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Chemours Co. is 0.44x versus 0.65x for Metallus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ingevity Corp. has a net margin of -3.62% compared to The Chemours Co.'s net margin of 12.25%. The Chemours Co.'s return on equity of -93.92% beat Ingevity Corp.'s return on equity of -37.98%.

The Chemours Co. has a consensus price target of $16.67, signalling downside risk potential of -2.19%. On the other hand Ingevity Corp. has an analysts' consensus of $70.75 which suggests that it could fall by -2%. Given that The Chemours Co. has more downside risk than Ingevity Corp., analysts believe Ingevity Corp. is more attractive than The Chemours Co..

The Chemours Co. has a beta of 1.629, which suggesting that the stock is 62.923% more volatile than S&P 500. In comparison Ingevity Corp. has a beta of 1.338, suggesting its more volatile than the S&P 500 by 33.774%.

The Chemours Co. has a quarterly dividend of $0.09 per share corresponding to a yield of 3.01%. Ingevity Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Chemours Co. pays 174.61% of its earnings as a dividend. Ingevity Corp. pays out -- of its earnings as a dividend.

The Chemours Co. quarterly revenues are $1.3B, which are larger than Ingevity Corp. quarterly revenues of $333.2M. The Chemours Co.'s net income of -$47M is lower than Ingevity Corp.'s net income of $40.8M. Notably, The Chemours Co.'s price-to-earnings ratio is 66.47x while Ingevity Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Chemours Co. is 0.44x versus 2.07x for Ingevity Corp.. Usually stocks with elevated PS ratios are considered overvalued.